Avalo Therapeutics (AVTX) EBIT Margin (2016 - 2025)
Avalo Therapeutics' (AVTX) quarterly EBIT Margin came in at 33461.02% in Q4 2025, down 2652820.0% YoY from N/an in Q4 2024, and down 382.65% on a QoQ basis from 6932.81% in Q4 2024.
Avalo Therapeutics (AVTX) EBIT Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of EBIT Margin data on file, last reported at 33461.02% in Q4 2025.
- Quarterly EBIT Margin fell 2652820.0% year-over-year to 33461.02% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 14585.0% (up 95105.0% YoY) and the FY2025 annual result came in at 123601.69%, down 10806609.0% from the prior year.
- EBIT Margin eased to 33461.02% in Q4 2025, from 6932.81% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 27.39% in Q3 2022 to a low of 33461.02% in Q4 2025.
- A 5-year average of 4782.2% and a median of 1588.98% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin jumped 721400 bps — and 2025, when it slumped 2652820 bps.
- Tracing AVTX's EBIT Margin over 5 years: stood at 8202.28% in 2021, then soared by 88 bps to 988.28% in 2022, then tumbled by 36 bps to 1341.16% in 2023, then slumped by 417 bps to 6932.81% in 2024, then sank by 383 bps to 33461.02% in 2025.
- The last three EBIT Margin figures came in at 33461.02% (Q4 2025), 6932.81% (Q4 2024), and 5165.06% (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -33,461.02% |
| Dec 31, 2024 | -6,932.81% |
| Sep 30, 2024 | -5,165.06% |
| Dec 31, 2023 | -1,341.16% |
| Sep 30, 2023 | -1,588.98% |
| Jun 30, 2023 | -1,111.98% |
| Mar 31, 2023 | -1,850.95% |
| Dec 31, 2022 | -988.28% |
| Sep 30, 2022 | 27.39% |
| Jun 30, 2022 | -1,145.01% |
| Mar 31, 2022 | -1,777.75% |
| Dec 31, 2021 | -8,202.28% |
| Sep 30, 2021 | -1,219.48% |
| Jun 30, 2021 | -510.55% |
| Mar 31, 2021 | -6,465.12% |
| Dec 31, 2020 | -1,091.45% |
| Sep 30, 2020 | -1,195.05% |
| Jun 30, 2020 | -883.03% |
| Mar 31, 2020 | -1,140.63% |
| Dec 31, 2019 | -143.18% |